( 15 ) noted higher RFS rates in patients achieving pCR or MPR, although this difference did not reach statistical significance, possibly due to the small sample size in the study.
← all excerpts
Meta-analysis of the efficiency and safety of neoadjuvant therapy with immune checkpoint inhibitors in resectable hepatocellular carcinoma.
1
—
—